AMP-activated protein kinase (AMPK) is an evolutionally conserved protein kinase that serves as an energy guardian to help cells adapt to various metabolic stress including hypoxia. Because the role of AMPK in cancers has not been fully elucidated, in this study we investigated the expression and activation of AMPK in lung adenocarcinoma (LADC) cells and tissue.

Further study details as provided by China Medical University Hospital:

Estimated Enrollment:

100

Study Start Date:

September 2010

Eligibility

Ages Eligible for Study:

25 Years to 85 Years

Genders Eligible for Study:

Both

Accepts Healthy Volunteers:

No

Sampling Method:

Non-Probability Sample

Study Population

Lung cancer received lobectomy in CMUH

Criteria

Inclusion Criteria:

Lung cancer received operation lobectomy in CMUH

Exclusion Criteria:

History of uremia, other malignant disease, and liver cirrhosis

History of pneumonia and pulmonary tuberculosis

History of long period of medications.

Contacts and Locations

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study.
To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below.
For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01249066